(APLT) Applied Therapeutics - Ratings and Ratios
Galactosemia, Diabetic Cardiomyopathy, Diabetic Neuropathy, Diabetic Retinopathy
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 148% |
| Value at Risk 5%th | 172% |
| Relative Tail Risk | -29.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.06 |
| Alpha | -105.63 |
| CAGR/Max DD | -0.38 |
| Character TTM | |
|---|---|
| Hurst Exponent | |
| Beta | 1.328 |
| Beta Downside | 1.629 |
| Drawdowns 3y | |
|---|---|
| Max DD | 97.94% |
| Mean DD | 44.19% |
| Median DD | 28.89% |
Description: APLT Applied Therapeutics October 19, 2025
Applied Therapeutics, Inc. (NASDAQ:APLT) is a clinical-stage biotech focused on novel therapeutics for high-unmet-need diseases in the U.S. Its lead candidate, AT-007, has finished Phase 3 trials in healthy adults for galactosemia and is now in a pediatric study, while also targeting sorbitol dehydrogenase deficiency and phosphomannomutase-CDG. The pipeline includes AT-001, in Phase 3 for diabetic cardiomyopathy and peripheral neuropathy, and AT-003, a preclinical program for diabetic retinopathy. The firm holds an exclusive license with Mercury Pharma Group to commercialize AT-007 and has been operating out of New York since its 2016 incorporation.
As of the latest 10-Q, APLT reported cash and cash equivalents of roughly $45 million, giving it an estimated 12-month runway at its current burn rate of $3-4 million per month. The biotech sector is currently benefiting from a 7 % YoY increase in R&D spending and a favorable FDA policy environment that has accelerated orphan-drug approvals, which could shorten time-to-market for AT-007 if it secures an orphan-drug designation. However, the company’s valuation is highly sensitive to Phase 3 readouts; a miss would likely depress the stock by 30-40 % based on historical outcomes for similar rare-disease programs.
For a deeper quantitative assessment, you might explore ValueRay’s analyst tools to model the potential impact of upcoming trial data on APLT’s valuation.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-18.1m TTM) > 0 and > 6% of Revenue (6% = 59.9k TTM) |
| FCFTA -2.53 (>2.0%) and ΔFCFTA -175.9pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -124.9% (prev 56.40%; Δ -181.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -2.53 (>3.0%) and CFO -86.8m <= Net Income -18.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (145.6m) change vs 12m ago 0.84% (target <= -2.0% for YES) |
| Gross Margin -1678 % (prev -177.7%; Δ -1500 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.42% (prev 9.38%; Δ -7.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.22 (EBITDA TTM -67.5m / Interest Expense TTM -82.5m) >= 6 (WARN >= 3) |
Altman Z'' -89.31
| (A) -0.04 = (Total Current Assets 31.7m - Total Current Liabilities 32.9m) / Total Assets 34.4m |
| (B) -18.51 = Retained Earnings (Balance) -636.4m / Total Assets 34.4m |
| warn (B) unusual magnitude: -18.51 — check mapping/units |
| (C) -1.43 = EBIT TTM -100.6m / Avg Total Assets 70.5m |
| (D) -18.21 = Book Value of Equity -636.3m / Total Liabilities 34.9m |
| Total Rating: -89.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 46.98
| 1. Piotroski 1.0pt |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity -4.46 |
| 5. Debt/Ebitda 0.14 |
| 7. RoE -65.63% |
| 8. Rev. Trend -0.51% |
| 9. EPS Trend 70.74% |
What is the price of APLT shares?
Over the past week, the price has changed by -16.69%, over one month by -75.67%, over three months by -54.29% and over the past year by -83.21%.
Is APLT a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the APLT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1.7 | 659.1% |
| Analysts Target Price | 1.7 | 659.1% |
| ValueRay Target Price | 0.2 | -18.2% |
APLT Fundamental Data Overview November 25, 2025
P/S = 37.3306
P/B = 7.7151
Beta = 1.93
Revenue TTM = 999.0k USD
EBIT TTM = -100.6m USD
EBITDA TTM = -67.5m USD
Long Term Debt = 2.50m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 467.0k USD (from shortTermDebt, last quarter)
Debt = 2.50m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.45m USD (from netDebt column, last quarter)
Enterprise Value = 27.9m USD (37.3m + Debt 2.50m - CCE 11.9m)
Interest Coverage Ratio = -1.22 (Ebit TTM -100.6m / Interest Expense TTM -82.5m)
FCF Yield = -311.4% (FCF TTM -86.8m / Enterprise Value 27.9m)
FCF Margin = -8693 % (FCF TTM -86.8m / Revenue TTM 999.0k)
Net Margin = -1816 % (Net Income TTM -18.1m / Revenue TTM 999.0k)
Gross Margin = -1678 % ((Revenue TTM 999.0k - Cost of Revenue TTM 17.8m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev none%)
Tobins Q-Ratio = 0.81 (Enterprise Value 27.9m / Total Assets 34.4m)
Interest Expense / Debt = 28.84% (Interest Expense 721.0k / Debt 2.50m)
Taxrate = 21.0% (US default 21%)
NOPAT = -79.5m (EBIT -100.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.96 (Total Current Assets 31.7m / Total Current Liabilities 32.9m)
Debt / Equity = -4.46 (negative equity) (Debt 2.50m / totalStockholderEquity, last quarter -561.0k)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -9.45m / EBITDA -67.5m)
Debt / FCF = 0.11 (negative FCF - burning cash) (Net Debt -9.45m / FCF TTM -86.8m)
Total Stockholder Equity = 27.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.77% (Net Income -18.1m / Total Assets 34.4m)
RoE = -65.63% (Net Income TTM -18.1m / Total Stockholder Equity 27.6m)
RoCE = -333.9% (out of range, set to none) (EBIT -100.6m / Capital Employed (Equity 27.6m + L.T.Debt 2.50m))
RoIC = -287.7% (out of range, set to none) (NOPAT -79.5m / Invested Capital 27.6m)
WACC = 11.66% (E(37.3m)/V(39.8m) * Re(10.91%) + D(2.50m)/V(39.8m) * Rd(28.84%) * (1-Tc(0.21)))
Discount Rate = 10.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.45%
Fair Price DCF = unknown (Cash Flow -86.8m)
EPS Correlation: 70.74 | EPS CAGR: 139.9% | SUE: 0.03 | # QB: 0
Revenue Correlation: -0.51 | Revenue CAGR: 12.92% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.045 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.41 | Chg30d=+0.123 | Revisions Net=+1 | Growth EPS=+24.4% | Growth Revenue=+25.0%
Additional Sources for APLT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle